• 1
    Anderson, J.E., Appelbaum, F.R., Fisher, L.D., Schoch, G., Shulman, H., Anasetti, C., Bensinger, W.I., Bryant, E., Buckner, C.D., Doney, K., Martin, P.J., Sanders, J.E., Sullivan, K.M., Thomas, E.D., Witherspoon, R.P., Hansen, J.A., Storb, R. (1993) Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood, 82, 677 681.
  • 2
    Aul, C., Runde, V., Gattermann, N., Germing, U., Schneider, W. (1994) Treatment of advanced primary myelodysplastic syndromes with AML-type chemotherapy: results in 76 patients. (Abstract). Leukemia Research, 18, (Suppl.), 22.
  • 3
    Aul, C., Runde, V., Germing, U., Burk, M., Heyll, A., Hildebrandt, B., Willers, R. (1995) Remission rates, survival and prognostic factors in 94 patients with advanced MDS treated with intensive chemotherapy. Annals of Hematology, 70, (Suppl. 2), A138.
  • 4
    Beck, J., Niethammer, D., Gekeler, V. (1996) MDR1, MRP, topoisomerase IIalpha/beta, and cyclin A gene expression in acute and chronic leukemias. Leukemia, 10, S39 S45.
  • 5
    Bennis, S., Ichas, F., Robert, J. (1995) Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line. International Journal of Cancer, 62, 283 290.
  • 6
    Bernstein, S., Brunetto, V., Davey, F., Mayer, R.J., Wurster-Hill, D., Schiffer, C., Bloomfield, C. (1993) Intensive chemotherapy for patients with myelodysplastic syndromes. Blood, 82, (Suppl. 1), 1960.
  • 7
    Campos, L., Guyotat, D., Archimbaud, E., Calmard-Oriol, P., Tsuruo, T., Troncy, J., Treille, D., Fiere, D. (1992) Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood, 79, 473 476.
  • 8
    Campos, L., Rouault, J.P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J.P., Guyotat, D. (1993) High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood, 81, 3091 3096.
  • 9
    Cheson, B.D., Jasperse, D.M., Simon, R., Friedman, M.A. (1986) A critical appraisal of low-dose Ara C in patients with acute non lymphocytic leukemia and myelodysplastic syndromes. Journal of Clinical Oncology, 4, 1857 1864.
  • 10
    Dalton, W.S., Crowley, J.J., Salmon, S.S., Grogan, T.W., Laufman, L.R., Weiss, G.R., Bonnet, J.D. (1995) A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: a Southwest Oncology Group study. Cancer, 75, 815 820.
  • 11
    De Witte, T., Muus, P., De Pauw, B., Haanen, C. (1990) Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer, 66, 831 837.
  • 12
    De Witte, T., Suciu, S., Peetermans, M., Fenaux, P., Strijckmans, P., Hayat, M., Jaksic, J., Selleslag, D., Zittoun, R., Dardenne, M., Solbu, G., Zwierzina, H., Muus, P. (1995) A pilot study of intensive chemotherapy for bad prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (SAML) following MDS of more than 6 months duration: a study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia, 9, 1805 1811.
  • 13
    Dorr, R.T. & Liddil, J.D. (1991) Modulation of mitomycin C-induced multidrug resistance in vitro. Cancer Chemotherapy and Pharmacology, 27, 290 294.
  • 14
    Estey, E.H., Kantarjian, H.M., O'Brien, S., Kornblau, S., Andreeff, M., Beran, M., Pierce, S., Keating, M. (1995) High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Cytokines and Molecular Therapy, 1, 21 28.
  • 15
    Fenaux, P. (1996) Myelodysplastic syndromes. Hematology and Cell Therapy, 38, 363 380.
  • 16
    Fenaux, P., Morel, P., Rose, C., Lai, J.L., Jouet, J.P., Bauters, F. (1991) Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. British Journal of Haematology, 77, 497 501.
  • 17
    Gajewski, J.L., Ho, W.G., Nimer, S.D., Hirji, K.F., Gekelman, L., Jacobs, A.D., Champlin, R.E. (1989) Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. Journal of Clinical Oncology, 7, 1637 1645.
  • 18
    Gardin, C., Chaibi, P., De Revel, T., Rousselot, P., Turlure, P., Micléa, J.M., Nédellec, G., Dombret, H. (1997) Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Leukemia, 11, 16 21.
  • 19
    Genne, P., Dimanche-Boitrel, M.T., Mauvernay, R.Y., Gutierrez, G., Duchamp, O., Petit, J.M., Martin, F., Chauffert, B. (1992) Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo. Cancer Research, 52, 2797 2801.
  • 20
    Genne, P., Duchamp, O., Solary, E., Pinard, D., Belon, J.P., Dimanche-Boitrel, M.T., Chauffert, B. (1994) Comparative effects of quinine and cinchonine in reversing multidrug resistance on human leukemic cell line K562/ADM. Leukemia, 8, 160 164.
  • 21
    George, S.L. & Desu, M.M. (1974) Planning the size and duration of a clinical trial studying the time to some critical event. Journal of Chronic Diseases, 27, 15 24.
  • 22
    Gieseler, F., Glasmacher, A., Kampfe, D., Wandt, H., Nuessler, V., Valsamas, S., Kunze, J., Wilms, K. (1996) Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines. Leukemia, 10, 1177 1180.
  • 23
    Gonzalez, O., Colombo, T., De Fusco, M., Imperatori, L., Zucchetti, M., D'Incalci, M. (1995) Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemotherapy and Pharmacology, 36, 335 340.
  • 24
    Gore, S.D. & Burke, P.J. (1995) Long-term survival of subsets of patients with advanced myelodysplastic syndromes (MDS) treated with intensive chemotherapy. (Abstract). Blood, 86, (Suppl. 1), 339a.
  • 25
    Guerci, A., Merlin, J.L., Missoum, N., Feldmann, L., Marchal, S., Witz, F., Rose, C., Guerci, O. (1995) Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood, 85, 2147 2153.
  • 26
    Hegewisch Becker, S. & Hossfeld, D.K. (1996) The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives. Annals of Hematology, 72, 105 117.
  • 27
    Hellström-Lingberg, E., Robert, K.H., Gahrton, G., Lindberg, G. (1992) A predictive model for the clinical response to low-dose Ara C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia. British Journal of Haematology, 81, 503 511.
  • 28
    Hiddemann, W., Büchner, T., Wörmann, B., Koch, P., Aul, C., Ballesen, L., Bennet, J. (1995) Intensive therapy of high risk myelodysplastic syndromes with sequential intermediate dose cytosine arabinoside and mitoxantrone with or without GM-CSF. (Abstract). Annals of Hematology, 70, (Suppl. II), A109.
  • 29
    Holmes, J., Wareing, C., Jacobs, A., Hayes, J.D., Padua, R.A., Wolf, C.R. (1990) Glutathione-s-transferase pi expression in leukaemia: a comparative analysis with mdr-1 data. British Journal of Cancer, 62, 209 212.
  • 30
    Hoyle, C.F., De Bastos, M., Wheatley, K., Sherrington, P.D., Fischer, P.J., Rees, J.K.H., Gray, R., Hayhoe, F.G.J. (1989) AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. British Journal of Haematology, 72, 45 53.
  • 31
    Kuwazuru, Y., Yoshimura, A., Hanada, S., Utsunomiya, A., Makino, T., Ishibashi, K., Kodama, M., Iwahashi, M., Arima, T., Akiyama, S. (1990) Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer, 66, 868 873.
  • 32
    Lepelley, P., Grardel, N., Preudhomme, C., Wattel, E., Cosson, A., Fenaux, P. (1998) Expression of LRP and its correlation with other drug resistance proteins and outcome in myelodysplastic syndromes (MDS). Leukemia and Lymphoma, in press.
  • 33
    Lepelley, P., Soenen, V., Preudhomme, C., Lai, J.L., Cosson, A., Fenaux, P. (1994) Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia, 8, 998 1004.
  • 34
    List, A.F. (1996) Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia, 10, 937 942.
  • 35
    List, A.F., Spier, C., Greer, J., Wolff, S., Hutter, J., Dorr, R., Salmon, S., Futscher, B., Baier, M., Dalton, W. (1993) Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. Journal of Clinical Oncology, 11, 1652 1660.
  • 36
    List, A.F., Spier, C.S., Grogan, T.M., Johnson, C., Roe, D.J., Greer, J.P., Wolff, S.N., Broxterman, H.J., Scheffer, G.L., Scheper, R.J., Dalton, W.S. (1996) Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood, 87, 2464 2469.
  • 37
    Marie, J.P., Huet, S., Faussat, A.M., Perrot, J.Y., Chevillard, S., Barbu, V., Bayle, C., Boutonnat, J., Calvo, F., Campos Guyotat, L., Colosetti, P., Cazin, J.L., De Cremoux, P., Delvincourt, C., Demur, C., Drenou, B., Fenneteau, O., Feuillard, J., Garnier Suillerot, A., Genne, P., Gorisse, M.C., Gosselin, P., Jouault, H., Lacave, R., Robert, J. (1997) Multicentric evaluation of the MDR phenotype in leukemia. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hôpitaux de Paris. Leukemia, 11, 1086 1094.
  • 38
    Marie, J.P., Legrand, O., Russo, D., Zhou, D., Suberville, A.M., Zittoun, R. (1992) Multidrug resistance (MDR) gene expression in acute non lymphoblastic leukemia: sequential analysis. Leukemia and Lymphoma, 8, 261 265.
  • 39
    Malayeri, R., Filipits, M., Suchomel, R.W., Züchbauer, S., Lechner, K., Pirker, R. (1996) Multidrug resistance in leukemias and its reversal. Leukemia and Lymphoma, 23, 451 458.
  • 40
    Martiat, P., Ferrant, A., Michaux, J.L., Sokal, G. (1988) Intensive chemotherapy for acute non-lymphoblastic leukemia after primary myelodysplastic syndrome. Hematological Oncology, 6, 299 305.
  • 41
    McKenna, S.L. & Padua, R.A. (1997) Multidrug resistance in leukaemia. British Journal of Haematology, 96, 659 74.
  • 42
    Michels, S.D., McKenna, R.W., Arthur, D.C., Brunning, R.D. (1985) Therapy related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood, 65, 1364 1372.
  • 43
    Miller, K.B., Kyungmann, K., Morrison, F.S., Winter, J.N., Bennett, J.M., Neiman, R.S., Head, D.R., Gassileth, P.A., O'Connell, M.J. (1992) The evaluation of low dose cytarabine in the treatment of myelodysplastic syndromes: a phase III intergroup study. Annals of Hematology, 65, 162 168.
  • 44
    Miller, T.P., Grogan, T.M., Dalton, W.S, Spier, C.M., Scheper, R.J., Salmon, S.E. (1991) P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. Journal of Clinical Oncology, 9, 17 24.
  • 45
    Morel, P., Declercq, C., Hebbar, M., Bauters, F., Fenaux, P. (1996) Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very-low risk group using standard mortality ratio techniques. British Journal of Haematology, 94, 116 119.
  • 46
    Morel, P., Hebbar, M., Lai, J.L., Duhamel, A., Preudhomme, C., Wattel, E., Bauters, F., Fenaux, P. (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia, 7, 1315 1323.
  • 47
    Mufti, G.J., Stevens, J.R., Oscier, D.G., Hamblin, T.J., Machin, D. (1985) Myelodysplastic syndromes: a scoring system with prognostic significance. British Journal of Haematology, 59, 425 433.
  • 48
    Oscier, D.G. (1987) Myelodysplastic syndromes. Clinical Haematology, 1, 389 426.
  • 49
    Pajeva, I.K., Wiese, M., Cordes, H.P., Seydel, J.K. (1996) Membrane interactions of some catamphiphilic drugs and relation to their multidrug-resistance-reversing ability. Journal of Cancer Research and Clinical Oncology, 122, 27 40.
  • 50
    Pirker, R., Wallner, J., Geissler, K., Linkesch, W., Haas, O.A., Bettelheim, P., Hopfner, M., Scherrer, R., Valent, P., Havelec, L., Ludwig, H., Lechner, K. (1991) MDR1 gene expression and treatment outcome in acute myeloid leukemia. Journal of the National Cancer Institute, 83, 708 712.
  • 51
    Poulain, S., Lepelley, P., Cambier, N., Coson, A., Fenaux, P., Wattel, E. (1998) Assessment of P-glycoprotein expression by immunocytochemistry and flow cytometry using two different monoclonal antibodies coupled with functional efflux analysis in 34 patients with acute leukemia. Drug Resistance in Leukemia and Lymphoma III. 3rd International Symposium on Drug Resistance in Leukemia and Lymphoma (ed. by G. J. L. Kaspers, R. Pieters and A. J. P. Veerman), in press.
  • 52
    Ruutu, T., Hänninen, A., Järventie, G., Koistinen, P., Koivunen, E., Kätkä, K., Nousiainen, T., Pelliniemi, T.T., Remes, K., Timonen, T., Volin, L., Elonen, E. (1994) Intensive treatment of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukaemia subsequent to MDS with idarubicin and cytarabine. (Abstract). British Journal of Haematology, 87, (Suppl. 1), 19.
  • 53
    Sato, H., Preisler, H., Day, R., Raza, A., Larson, R., Browman, G., Goldberg, J., Vogler, R., Grunwald, H., Gottlieb, A., Bennett, J., Gottesman, M., Pastan, I. (1990) MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. British Journal of Haematology, 75, 340 345.
  • 54
    Solary, E., Bidan, J.M., Calvo, F., Chauffert, B., Caillot, D., Mugneret, F., Gauville, C., Tsuruo, T., Carli, P.M., Guy, H. (1991a) P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukemia and myeloma. Leukemia, 5, 592 597.
  • 55
    Solary, E., Caillot, D., Chauffert, B., Casasnovas, R.O., Dumas, M., Maynadie, M., Guy, H. (1992) Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. Journal of Clinical Oncology, 10, 1730 1736.
  • 56
    Solary, E., Velay, I., Chauffert, B., Bidan, J.M., Caillot, D., Dumas, M., Guy, H. (1991b) Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. Cancer, 68, 1714 1719.
  • 57
    Solary, E., Velay, I., Chauffert, B., Caillot, D., Bidan, J.M., Dumas, M., Casasnovas, O., Guy, H. (1990) Quinine circumvents the doxorubicin resistance of a multidrug resistant human leukaemic cell-line, K562/DXR. Nouvelle Revue Française d'Hematologie, 32, 361 363.
  • 58
    Solary, E., Witz, B., Caillot, D., Moreau, P., Desablens, B., Cahn, J.Y., Sadoun, A., Pignon, B., Berthou, C., Maloisel, F., Guyotat, D., Casassus, P., Ifrah, N., Lamy, Y., Audhuy, B., Colombat, P., Harousseau, J.L. (1996) Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood, 88, 1198 1205.
  • 59
    Sonneveld, P. (1996) Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies. European Journal of Cancer, 6, 1062 1069.
  • 60
    Sonneveld, P., Marie, J.P., Huisman, C., Vekhoff, A., Schoester, M., Faussat, A.M., Van Kapel, J., Groenewegen, A., Charnick, S., Zittoun, R., Lowenberg, B. (1996) Reversal of multidrug resistnace by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma: a phase I study. Leukemia, 10, 1741 1750.
  • 61
    Sutton, L., Chastang, C., Ribaud, P., Jouet, J.P., Kuentz, M., Attal, M., Reiffers, J., Tigaud, J.M., Rio, B., Dauriac, C., Legros, M., Dreyfus, F., Lioure, B., Troussard, X., Milpied, N., Witz, F., Oriol, P., Cahn, J.Y., Michallet, M., Gluckman, E., Ifrah, N., Pico, J.L., Vilmer, E., Leblond, V. (1996) Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients. Société Française de Greffe de Moelle. Blood, 88, 358 365.
  • 62
    Wattel, E., De Botton, S., Laï, J.L., Preudhommme, C., Lepelley, P., Bauters, F., Fenaux, P. (1997) Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long survivors and outcome of partial responders. British Journal of Haematology, 98, 983 991.
  • 63
    Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P., Fenaux, P. (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 84, 3148 3157.
  • 64
    Weber, D., Dimopoulos, M., Sinicrope, F., Alexanian, R. (1995) VAD-cyclosporine therapy for VAD-resistant multiple myeloma. Leukemia and Lymphoma, 19, 159 163.
  • 65
    Wigler, P.W. & Patterson, F.K. (1994) Reversal agent inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochimica et Biophysica Acta, 1189, 1 6.
  • 66
    Wilson, W.H., Bates, S.E., Fojo, A., Bryant, G., Zhan, Z., Regis, J., Wittes, R.E., Jaffe, E.S., Steinberg, S.M., Herdt, J., Chabner, B.A. (1995) Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. Journal of Clinical Oncology, 13, 1995 2004.
  • 67
    Wood, P., Burgess, R., MacGregor, A., Yin, Y.A. (1994) P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. British Journal of Haematology, 87, 509 514.
  • 68
    Zöchbauer, S., Gsur, A., Brunner, R., Kyrle, P.A., Lechner, K., Pirker, R. (1994) P-glycoprotein expression as unfavourable prognostic factor in acute myeloid leukemia. Leukemia, 8, 974 977.